McCormick Place Convention Center
Meet the ClearNote Health team at ASCO 2026
ClearNote Health will be at ASCO 2026 presenting landmark new clinical data from our multi-cohort validation study for pancreatic cancer early detection using liquid biopsy.
Connect with our team to explore the latest from Virtuoso™, our epigenomic liquid biopsy platform, and Avantect®, our multiomics early detection test. We'd love to find time to connect.
ClearNote Health is presenting new multi-cohort validation data supporting the clinical utility of our multi-analyte liquid biopsy approach for pancreatic cancer early detection.
Explore our complementary platforms — one powering oncology drug research and development, the other delivering early detection for pancreatic cancer.
Genome-wide epigenetic insights into cancer biology, treatment response and resistance, all from a simple blood draw.
Learn more
Multiomics liquid biopsy for the early detection of high mortality cancers, delivering unsurpassed accuracy for pancreatic cancer with 82.6% sensitivity and 97.5% specificity. Now available in over 70 countries.
Learn moreOur team will be available throughout the conference for meetings and conversations.
Go deeper on the science and clinical data behind our platforms.
Explore how genome-wide epigenetic profiling from a simple blood draw is transforming oncology drug research and development.
Learn how Avantect® combines multiple biomarker types to deliver superior performance for early detection of pancreatic cancer.
Book time with our team or arrange a dedicated meeting during the conference.
Schedule a Meeting